Loading...

Financial Summary


Dova Pharmaceuticals Inc.

Dova Pharmaceuticals Inc. (DOVA)

Healthcare
Buy
B+
Market Info
Financial Info
Financial Modelling
Symbol DOVA
Price 14.5$
Beta 2.04
Volume Avrg. 0.18M
Market Cap 0.40B
Shares (2018) 27,803.17K
Last Div 0
Dividend Yield -
DCF Unlevered -
DCF Levered -
ROE -94.66% Strong Sell
ROA -78.00% Strong Sell
Operating Margin -686.14% Strong Sell
Debt / Equity 26.99% Neutral
P/E - Neutral
P/B 2.80 Strong Buy

Income Statement

Download DOVA income statement Download DOVA income statement
Year 201620172018
Revenue --10.36
Cost of Revenue --1.18
Gross Profit --9.18
R&D Expenses 27.7915.7118.30
Sales, General and Administrative Expense 1.6013.5061.92
Operating Expenses 29.3929.2180.22
Operating Income -29.39-29.21-71.05
Interest Expense -0.211.231.88
Earnings before Tax -36.25-29.95-72.28
Income Tax Expense ---
Net Income -36.25-29.95-72.28
Net Income - Non-Controlling int ---
Net Income - Discounted ops ---
Net Income Com -36.25-29.95-72.28
Preferred Dividends ---
Earnings Per Share Basic --1.40-2.60
Earnings Per Share Diluted --1.40-2.60
Weighted Average Shares Outstanding -21.4427.80
Weighted Average Shares Outstanding (Diluted) -21.4427.80
Dividend per Share ---
Gross Margin --0.89
EBITDA Margin ---6.80
EBIT Margin ---6.80
Profit Margin ---6.98
Free Cash Flow margin ---0.00
EBITDA --28.72-70.37
EBIT -29.39-28.72-70.41
Consolidated Income --29.95-72.28
Earnings Before Tax Margin ---6.98
Net Profit Margin ---6.98

Balance Sheet Statement

Download DOVA income statement Download DOVA income statement
Year 201620172018
Cash and cash equivalents 28.7194.85104.57
Short-term investments ---
Cash and short-term investments 28.7194.85104.57
Receivables --0.61
Inventories --4.39
Property, Plant & Equipment Net -0.060.36
Goodwill and Intangible Assets ---
Long-term investments ---
Tax assets ---
Total non-current assets --16.31
Total current assets -0.060.36
Total assets 28.7596.38112.17
Payables 0.161.360.82
Short-term debt -30.216.67
Total current liabilities 8.3135.2019.50
Long-term debt 13.64-13.94
Total debt -30.2120.61
Deferred revenue --2.37
Tax Liabilities ---
Deposit Liabilities ---
Total non-current liabilities --16.31
Total liabilities 21.9535.2035.81
Other comprehensive income ---
Retained earnings (deficit) -27.19-57.15-129.43
Total shareholders equity 6.7961.1876.36
Investments ---
Net Debt -15.07-64.63-83.96
Other Assets 0.041.472.24
Other Liabilities 8.153.6312.01

Cash Flow Statement

Download DOVA income statement Download DOVA income statement
Year 201620172018
Depreciation & Amortization --0.03
Stock-based compensation -5.6312.49
Operating Cash Flow -1.32-10.90-53.67
Capital Expenditure -0.06-0.06-0.37
Acquisitions and disposals ---
Investment purchases and sales ---
Investing Cash Flow ---
Insurance (repayment) of debt ---
Insurance (buybacks) of shares ---
Dividend payments ---
Financing Cash Flow 39.5978.1063.75
Effect of forex changes on cash ---
Net cash flow / Change in cash -66.149.72
Free Cash Flow --10.96-54.03
Net Cash/Marketcap -0.000.00

Retained Earning Schedule

Year 201620172018
Retained Earnings (Previous Year) --27-57
Net Income -36-30-72
Stock Dividends 9--
Divident Paid ---
Retained Earnings -27-57-129
Year 201620172018
Gross PPE --0
Annual Depreciation 001
Capital Expenditure -0-0-0
Net PPE -00

Intangible and Goodwill Schedule

Year 201620172018
Intangible and Goodwill (Previous Year) ---
New Purchases ---
Intangible and Goodwill ---
Dova Pharmaceuticals Inc.

Dova Pharmaceuticals Inc. (DOVA)

14.5
-0.09 (-0.62%)

About


Alex Sapir
Healthcare
Biotechnology
NASDAQ Global Market

Dova Pharmaceuticals Inc is a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases that are treated by specialist physicians, with an initial focus on addressing thrombocytopenia.